Trial Profile
A multicenter pilot phase II study for the preliminary evaluation of feasibility, activity and safety of the administration of Bendamustine and Ofatumumab in combination in marginal zone B-cell lymphomas (MZL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Ofatumumab (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- 01 Feb 2021 Results published in the Hematological Oncology
- 26 Jan 2017 Status changed from recruiting to completed.
- 03 Aug 2012 New trial record